| Autor: |
French MA; School of Pathology and Laboratory Medicine, University of Western Australia, Perth 6009, Australia. martyn.french@uwa.edu.au.; Department of Clinical Immunology, Royal Perth Hospital and PathWest Laboratory Medicine, Perth 6000, Australia. martyn.french@uwa.edu.au., Abudulai LN; School of Pathology and Laboratory Medicine, University of Western Australia, Perth 6009, Australia., Fernandez S; School of Pathology and Laboratory Medicine, University of Western Australia, Perth 6009, Australia. |
| Jazyk: |
angličtina |
| Zdroj: |
Vaccines [Vaccines (Basel)] 2013 Aug 09; Vol. 1 (3), pp. 328-42. Date of Electronic Publication: 2013 Aug 09. |
| DOI: |
10.3390/vaccines1030328 |
| Abstrakt: |
The development of vaccines to treat and prevent human immunodeficiency virus (HIV) infection has been hampered by an incomplete understanding of "protective" immune responses against HIV. Natural control of HIV-1 infection is associated with T-cell responses against HIV-1 Gag proteins, particularly CD8⁺ T-cell responses restricted by "protective" HLA-B alleles, but other immune responses also contribute to immune control. These immune responses appear to include IgG antibodies to HIV-1 Gag proteins, interferon-a-dependant natural killer (NK) cell responses and plasmacytoid dendritic cell (pDC) responses. Here, it is proposed that isotype diversification of IgG antibodies against HIV-1 Gag proteins, to include IgG2, as well as IgG3 and IgG1 antibodies, will broaden the function of the antibody response and facilitate accessory cell responses against HIV-1 by NK cells and pDCs. We suggest that this should be investigated as a vaccination strategy for HIV-1 infection. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
